Cerenome, Inc. (CNSY)
1.93
+0.14
(+7.82%)
USD |
NASDAQ |
Oct 09, 16:00
1.94
+0.01
(+0.52%)
After-Hours: 20:00
Cerenome Net Income (Quarterly) : -9.006M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.006M |
| March 31, 2026 | -6.946M |
| December 31, 2025 | -5.713M |
| September 30, 2025 | -4.423M |
| June 30, 2025 | 1.191M |
| March 31, 2025 | -17.40M |
| December 31, 2024 | -3.903M |
| September 30, 2024 | -2.874M |
| June 30, 2024 | -2.94M |
| March 31, 2024 | -3.261M |
| December 31, 2023 | -3.81M |
| September 30, 2023 | -3.219M |
| June 30, 2023 | -1.482M |
| March 31, 2023 | -4.805M |
| December 31, 2022 | -5.658M |
| September 30, 2022 | -5.219M |
| June 30, 2022 | -5.282M |
| March 31, 2022 | -4.116M |
| December 31, 2021 | -4.155M |
| September 30, 2021 | -3.724M |
| June 30, 2021 | -2.80M |
| March 31, 2021 | -2.72M |
| December 31, 2020 | -3.587M |
| September 30, 2020 | -1.728M |
| June 30, 2020 | -1.839M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.087M |
| December 31, 2019 | 0.92M |
| September 30, 2019 | 0.526M |
| June 30, 2019 | -2.267M |
| March 31, 2019 | -2.464M |
| December 31, 2018 | -2.01M |
| September 30, 2018 | -1.396M |
| June 30, 2018 | -2.285M |
| March 31, 2018 | -4.409M |
| December 31, 2017 | -8.264M |
| September 30, 2017 | -4.807M |
| June 30, 2017 | -6.049M |
| March 31, 2017 | -7.544M |
| December 31, 2016 | -4.919M |
| September 30, 2016 | -5.384M |
| June 30, 2016 | -6.405M |
| March 31, 2016 | -5.339M |
| December 31, 2015 | -2.756M |
| September 30, 2015 | 1.527M |
| June 30, 2015 | 4.45M |
| March 31, 2015 | -22.62M |
| December 31, 2014 | -6.924M |
| September 30, 2014 | -9.385M |
| June 30, 2014 | -11.83M |
| March 31, 2014 | -10.40M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Ernexa Therapeutics, Inc. | -4.009M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.411M |
| Total Expenses (Quarterly) | 9.417M |
| EPS Diluted (Quarterly) | -1.305 |
| Enterprise Value | 4.542M |
| Gross Profit Margin (Quarterly) | 63.26% |
| Profit Margin (Quarterly) | -2.19K% |
| Earnings Yield | -228.5% |
| Normalized Earnings Yield | -228.49 |